Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Bortezomib (2)
- Multiple Myeloma (2)
- Myeloid Cell Leukemia Sequence 1 Protein (2)
- Antiapoptitic proteins (1)
- Anticoagulants (1)
-
- Antineoplastic agents (1)
- Apoptosis Regulatory Proteins (1)
- Blood Coagulation Disorders (1)
- Bone marrow (1)
- Bortezomib Resistance (1)
- CXCR4 (1)
- Cardiotoxicity (1)
- Carfilzomib (1)
- Case Reports (1)
- Drug Resistance (1)
- Factor Xa Inhibitors (1)
- Mcl-1 (1)
- Multiple myeloma (1)
- Proteasome Inhibitors (1)
- Protein S (1)
- Protein S Deficiency (1)
- Stroke (1)
- Tumor microenvironment (1)
Articles 1 - 4 of 4
Full-Text Articles in Hematology
Efficacy Of Mcl-1 Inhibitors In Multiple Myeloma Cells Resistant To Bortezomib, Emily Nelson, Omar S. Al-Odat, Sabrina M. Paparo, Daniel A. Guirguis, Gabriella Yao, Manoj Pandey, Subash Jonnalagadda, Tulin Budak-Alpdogan
Efficacy Of Mcl-1 Inhibitors In Multiple Myeloma Cells Resistant To Bortezomib, Emily Nelson, Omar S. Al-Odat, Sabrina M. Paparo, Daniel A. Guirguis, Gabriella Yao, Manoj Pandey, Subash Jonnalagadda, Tulin Budak-Alpdogan
Rowan-Virtua Research Day
Multiple myeloma (MM) is a type of cancer that affects plasma B cells. Patients with MM often experience frequent relapses and can develop resistance to drugs. As a medical researcher, it is important to understand the role of Mcl-1 in preventing intrinsic apoptosis and drug resistance. Mcl-1 belongs to the anti-apoptotic subgroup of Bcl-2 family proteins and plays a crucial role in these processes. Mcl-1 plays a crucial role in driving disease progression and contributing to drug resistance in MM. It has been observed that there is an increased expression of Mcl-1 in 52% of patients with MM during diagnosis, …
Stroke In Hfref Without Atrial Fibrillation And Concurrent Protein S Deficiency: What Is The Best Treatment?, Rohan Umrani, Trinava Roy, Bhavana Kadiyala, Yvette Wang
Stroke In Hfref Without Atrial Fibrillation And Concurrent Protein S Deficiency: What Is The Best Treatment?, Rohan Umrani, Trinava Roy, Bhavana Kadiyala, Yvette Wang
Rowan-Virtua Research Day
Hypercoagulable disorders are often the culprit for repeated strokes in young patients, with or without other comorbidities
Medications typically used for stroke prophylaxis:
- Warfarin
- Aspirin
- Direct Oral Anticoagulants (DOACs)
Warfarin is the preferred method of anticoagulation for stroke prophylaxis in patients with hypercoagulable disorders
A deficiency of protein S increases the risk of pro coagulation due to a relative deficiency of anticoagulants.
Patients with protein S deficiency tend to have recurrent venous thromboses and pulmonary emboli
The Effect Of Carfilzomib And Bortezomib Based Regimes On Cardiotoxicity In Multiple Myeloma Patients At Cooper University Hospital, Ami Patel, Tulin Budak-Alpdogan, Stalam Tapati
The Effect Of Carfilzomib And Bortezomib Based Regimes On Cardiotoxicity In Multiple Myeloma Patients At Cooper University Hospital, Ami Patel, Tulin Budak-Alpdogan, Stalam Tapati
Rowan-Virtua Research Day
Introduction
- Multiple myeloma (MM) is a cancer of plasma cells, which is a white blood cell that normally produces antibodies
- Treatment in patients younger than 65 years old is typically high dose chemotherapy, usually with bortezomib based regimens or lenalidomide dexamethasone, followed by a stem cell transplant
- For patients with relapsed myeloma, carfilzomib is usually the treatment of choice
- Carfilzomib is a highly selective, irreversible proteasome inhibitor that binds to the 20 S proteasome. Several studies have illustrated that carfilzomib has been associated with cardiovascular adverse events (CVAE).
- Current literature on the role and effect of bortezomib on cardiotoxicity is …
Development Of Novel Dual Inhibitor Of Chemokine Receptor 4 And Mcl-1 Against Multiple Myeloma, Kuntal Bhowmick, Kristy K. Patel, Suman Pathi, Subash Jonnalagadda, Tulin Budak-Alpdogan, Manoj K. Pandey
Development Of Novel Dual Inhibitor Of Chemokine Receptor 4 And Mcl-1 Against Multiple Myeloma, Kuntal Bhowmick, Kristy K. Patel, Suman Pathi, Subash Jonnalagadda, Tulin Budak-Alpdogan, Manoj K. Pandey
Rowan-Virtua Research Day
Multiple myeloma (MM) is a neoplastic plasma-cell disorder. This is characterized by clonal proliferation of malignant plasma cells in the bone-marrow (BM) microenvironment, monoclonal protein in blood or urine, and associated organ dysfunction. The treatment options approved by FDA are immune-modulatory agents, proteasome inhibitors, and autologous stem cell transplantation (ASCT). Unfortunately, MM remains uniformly fatal owing to intrinsic or acquired drug resistance and the median survival time is 3 to 5 years. Thus, there is a great need for novel strategies to combat MM.
The intimate relationship of myeloma cells to BM microenvironment is “hallmark of myeloma”. The homing of …